Atacicept

Drug Profile

Atacicept

Alternative Names: Anti-Blys/anti-APRIL fusion protein; TACI-Ig

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ZymoGenetics
  • Developer EMD Serono; Merck Serono; ZymoGenetics
  • Class Antirheumatics; Recombinant fusion proteins
  • Mechanism of Action B cell activating factor inhibitors; Tumour necrosis factor ligand superfamily member 13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Systemic lupus erythematosus
  • Phase II IgA nephropathy
  • Discontinued Chronic lymphocytic leukaemia; Lupus nephritis; Multiple myeloma; Multiple sclerosis; Non-Hodgkin's lymphoma; Rheumatoid arthritis

Most Recent Events

  • 14 Jun 2017 Efficacy, immunogenicity and adverse events data from an extension of the phase IIb Address II trial in Systemic lupus erythematosus presented at the 18th Annual Congress of the European League Against Rheumatism (EULAR-2017)
  • 31 Jan 2017 Phase-II clinical trials in IgA nephropathy in USA (SC) (NCT02808429)
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top